Madeleine Heck, MD
Infectious Disease · Baton Rouge, LANPI 1407877426
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 39.9% of the total. Reporting peaked in 2021 at $248 and has fallen 89.6% since, to $26 in 2024. That places this record below the midpoint for infectious disease clinicians in LA, where the typical reported total is $611.
Across 10 payments — averaging $61.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$244
- Daiichi Sankyo Inc.$118
- La Jolla Pharmaceutical Company$92
- W. L. Gore & Associates, Inc.$67
- Melinta Therapeutics, LLC$26
- Paratek Pharmaceuticals, Inc.$22
- plus $42 from 3 others
What the payments were for
- Food & beverage$611100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $244 |
| Daiichi Sankyo Inc. | 1 | $118 |
| La Jolla Pharmaceutical Company | 1 | $92 |
| W. L. Gore & Associates, Inc. | 1 | $67 |
| Melinta Therapeutics, LLC | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Theratechnologies Inc. | 1 | $19 |
| Merck | 1 | $12 |
| Biofire Diagnostics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$244
- INJECTAFER$118
How this compares
$611 in reported general payments places this provider in the 50th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $45,953 |
| Daptomycin | 21 | $19,579 |
| Amoxicillin | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Baton Rouge
- Walter CampbellBaton Rouge$6K
- Waref AzmehBaton Rouge$2K
- Maria Reyes AngelesBaton Rouge$2K
- Breanna CampbellBaton Rouge$1K
- Patrick NjokuBaton Rouge$979
- Scott AndersonBaton Rouge$937
- Shobha Rani VootukuriBaton Rouge$881
- John NnadiBaton Rouge$491
- Hector Brunet RodriguezShreveport$592K
- Guillermo Padilla-PinedaShreveport$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.